| 1 |
NCT03024463 |
Recruiting |
The Validation Study of Internal Mammary Lymph Biopsy in Breast Cancer Patients |
|
- Procedure: IM-SLNB and IMLN dissection
|
Observational |
|
- Shandong Cancer Hospital and Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- The accuracy (false negative rate) of internal mammary sentinel lymph node biopsy
- The number of internal mammary non-sentinel lymph node metastases in patients with positive axillary node and internal mammary sentinel lymph node
- Factors influencing the number of internal mammary non-sentinel lymph node metastases in patients with positive axillary node and internal mammary sentinel lymph node
|
200 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT03024463 |
IMLN-VS |
|
August 1, 2017 |
March 1, 2019 |
August 1, 2019 |
January 18, 2017 |
March 20, 2018 |
|
- Shandong Cancer Hospital and Institute
Jinan, Shandong, China
|
| 2 |
NCT02489448 |
Recruiting |
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer |
|
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathologic Complete Response (pCR)
|
61 |
All |
18 Years and older (Adult, Senior) |
NCT02489448 |
1409014537 |
|
November 2015 |
October 2018 |
October 2019 |
July 3, 2015 |
October 25, 2017 |
|
- Yale School of Medicine
New Haven, Connecticut, United States
|
| 3 |
NCT02258451 |
Recruiting |
Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer |
|
- Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
- Drug: Placebo (saline)
- Drug: Exemestane
- Drug: Everolimus
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Symptomatic skeletal event free survival (SSE-FS).
- Overall survival
- Time to opiate use for cancer pain
- (and 6 more...)
|
311 |
Female |
18 Years and older (Adult, Senior) |
NCT02258451 |
17096
2014-002114-23 |
|
June 4, 2015 |
August 31, 2018 |
March 15, 2019 |
October 7, 2014 |
April 13, 2018 |
|
- Yuma, Arizona, United States
- Bakersfield, California, United States
- La Jolla, California, United States
- (and 172 more...)
|
| 4 |
NCT02834494 |
Recruiting |
Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave), |
|
- Procedure: 3D Shear Wave Elastography (SWE)
- Biological: Biopsy
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Assess the accuracy of the sequential measurements by 3D Shear Wave Elastography (SWE) for predicting histological response to neoadjuvant chemotherapy
- Elastic properties before treatment (especially ratio between tumor and glandular breast or fat tissues close to the tumors)
- peritumoral environmental elasticity properties
- (and 8 more...)
|
140 |
All |
18 Years and older (Adult, Senior) |
NCT02834494 |
IC 2015-07 |
NEO-ELASTO |
February 2016 |
October 2018 |
October 2018 |
July 15, 2016 |
July 13, 2017 |
|
- Institut Curie Paris
Paris, France
|
| 5 |
NCT02776917 |
Not yet recruiting |
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
|
- Drug: Cirmtuzumab + Paclitaxel
|
Interventional |
Phase 1 |
- Barbara Parker, MD
- University of California, San Diego
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the maximum tolerated dose (MTD)
- Determine the rate of dose limiting toxicities (DLTs)
- Treatment-emergent adverse events
- (and 2 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT02776917 |
160178 |
|
January 2018 |
January 2019 |
January 2020 |
May 18, 2016 |
May 12, 2017 |
|
- University of California, San Diego
La Jolla, California, United States
|
| 6 |
NCT02948764 |
Recruiting |
Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy After Neoadjuvant Chemotherapy in Breast Cancer |
|
- Device: Vacuum-Assisted Biopsy
|
Interventional |
Not Applicable |
- Heidelberg University
- German Research Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- false negative VAB results, reported as the false negative rate (= FNR)
- negative predictive value (NPV)
- positive predictive value (PPV)
- false positive rate (FPR)
|
600 |
Female |
18 Years and older (Adult, Senior) |
NCT02948764 |
2 |
RESPONDER |
January 2017 |
September 2018 |
December 2019 |
October 28, 2016 |
March 31, 2017 |
|
- University Breast Unit, Department of Gynecology, University of Heidelberg
Heidelberg, Baden-Württemberg, Germany
|
| 7 |
NCT02781259 |
Recruiting |
Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer |
|
- Procedure: Axillary lymph node dissection
- Drug: Indocyanine green
- Device: Imaging devices
|
Interventional |
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of metastatic lymph nodes in fluorescent positive lymph nodes and fluorescent negative lymph nodes confirmed by pathologist
- Clinicopathological factors associated with lymph node metastasis in fluorescent negative lymph nodes
|
150 |
Female |
20 Years to 70 Years (Adult, Senior) |
NCT02781259 |
2015-01-046-007 |
|
May 2016 |
February 2017 |
April 2017 |
May 24, 2016 |
September 20, 2016 |
|
- Samsung medical center
Seoul, Korea, Republic of
|
| 8 |
NCT02774473 |
Recruiting |
[18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy |
|
- Device: [18F]FLT PET/CT
- Drug: Paclitaxel
|
Interventional |
Not Applicable |
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Intervention Model: Single Group Assignment
- Primary Purpose: Diagnostic
|
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02774473 |
UPCC 11115 |
|
February 2016 |
February 2020 |
|
May 17, 2016 |
July 31, 2017 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 9 |
NCT03277898 |
Not yet recruiting |
Aerobic Exercise and Cognitive Functioning in Women With Breast Cancer |
|
- Behavioral: Aerobic Exercise
- Behavioral: Usual Care (Wait-list Control)
|
Interventional |
Not Applicable |
- University of British Columbia
- Canadian Cancer Society Research Institute (CCSRI)
- Canadian Breast Cancer Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change with treatment and maintenance post-treatment in objective neuropsychology test battery composite score
- Change with treatment and maintenance post-treatment in self-reported cognitive function and impact on quality of life
- Change with treatment and maintenance post-treatment in self-reported cognitive function
- (and 2 more...)
|
84 |
Female |
19 Years to 65 Years (Adult) |
NCT03277898 |
H17-00563 |
ACTIVATE |
November 1, 2017 |
November 1, 2019 |
November 1, 2020 |
September 11, 2017 |
September 11, 2017 |
|
- Breast Cancer Training Center, 614 W. 8th Ave
Vancouver, British Columbia, Canada - Clinical Exercise Physiology Lab
Vancouver, British Columbia, Canada - School of Human Kinetics - University of Ottawa
Ottawa, Ontario, Canada - School of Human Kinetics - University of Ottawa
Ottawa, Ontario, Canada
|
| 10 |
NCT03069742 |
Recruiting |
Study of Web-based Decision Aids for Increasing Breast Cancer Chemoprevention in the Primary Care Setting |
|
- Other: RealRisks
- Other: BNAV
|
Interventional |
Not Applicable |
- Columbia University
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Chemoprevention uptake rate among high-risk women
- Chemoprevention intention rate among high-risk women (Likert Scale Score)
- High-risk referral rates to the breast clinic
- Completion of high-risk consultations at the breast clinic
|
350 |
Female |
35 Years to 75 Years (Adult, Senior) |
NCT03069742 |
AAAP4151 II
R01CA177995 |
|
November 2016 |
April 2019 |
April 2019 |
March 3, 2017 |
May 11, 2017 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 11 |
NCT03250676 |
Recruiting |
Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer |
|
|
Interventional |
Phase 1
Phase 2 |
- H3 Biomedicine Inc.
- Eisai Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Number of participants with dose-limiting toxicities (DLTs), as a function of the dose of H3B-6545 for determination of the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
- Phase 2: Objective Response Rate (ORR)
- Phase 1 and Phase 2: Number of participants with any treatment-emergent (TE) serious adverse event (SAE)
- (and 27 more...)
|
110 |
Female |
18 Years and older (Adult, Senior) |
NCT03250676 |
H3B-6545-A001-101
BRE 287 |
|
August 18, 2017 |
December 2018 |
April 2019 |
August 16, 2017 |
December 20, 2017 |
|
- Florida Cancer Specialists and Research Institute
Sarasota, Florida, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Tennessee Oncology
Nashville, Tennessee, United States
|
| 12 |
NCT03389204 |
Not yet recruiting |
Upper Limb Function After Breast Cancer Surgery: the Role of Post-operative Physical Therapy Intervention |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mobility of upper limb
- lymphedema
- Shoulder pain
|
1200 |
Female |
18 Years to 65 Years (Adult) |
NCT03389204 |
AMC2020-17 |
|
April 1, 2018 |
July 1, 2019 |
September 1, 2019 |
January 3, 2018 |
February 13, 2018 |
|
- Assuta Medican Center
Tel Aviv, Israel
|
| 13 |
NCT03272477 |
Recruiting |
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients |
|
- Drug: Perjeta Injectable Product
- Drug: Herceptin
- Drug: Tamoxifen
- (and 11 more...)
|
Interventional |
Phase 2 |
- Palleos Healthcare GmbH
- Roche Pharma AG
- WSG WOMEN´S HEALTHCARE STUDY GROUP
- CANKADO
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathological complete response (pCR)
- Health-related quality of life using EORTC QBL-BR-23 scale
- Health-related quality of life using EQ5D-5L scale
- (and 6 more...)
|
259 |
Female |
18 Years and older (Adult, Senior) |
NCT03272477 |
PH002-TP-II |
TP-II |
August 22, 2017 |
March 15, 2020 |
November 15, 2024 |
September 5, 2017 |
September 20, 2017 |
|
- Evangelisches Krankenhaus Bethesda Mönchengladbach
Mönchengladbach, Germany
|
| 14 |
NCT03310957 |
Recruiting |
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
|
- Drug: SGN-LIV1A
- Drug: Pembrolizumab
|
Interventional |
Phase 1
Phase 2 |
- Seattle Genetics, Inc.
- Merck Sharp & Dohme Corp.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Confirmed objective response rate
- Incidence of adverse events
- Incidence of laboratory abnormalities
- (and 5 more...)
|
72 |
All |
18 Years and older (Adult, Senior) |
NCT03310957 |
SGNLVA-002
KEYNOTE 721 |
|
February 27, 2018 |
May 2020 |
May 2020 |
October 16, 2017 |
April 3, 2018 |
|
- Chao Family Comprehensive Cancer Center University of California Irvine
Orange, California, United States - Helen F. Graham Cancer Center / Christiana Care Health Systems
Newark, Delaware, United States - Ingalls Cancer Care / Ingalls Memorial Hospital
Harvey, Illinois, United States - (and 4 more...)
|
| 15 |
NCT03283384 |
Not yet recruiting |
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. |
|
- Drug: Letrozole
- Drug: Chemotherapy
- Drug: Ribociclib plus letrozole
|
Interventional |
Phase 2 |
- Borstkanker Onderzoek Groep
- Novartis
- Philips Healthcare
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Difference in complete cell cycle arrest (CCCA; defined as Ki67 IHC <1%) between ribociclib plus letrozole and chemotherapy in the surgical specimen.
- Correlation between Ki67 IHC scored manually, IHC scored automatically (Vectra ® 3) and Ki67 mRNA.
- Correlation between ER pathway activity at baseline, after two weeks letrozole and at surgery and clinical outcome.
- (and 6 more...)
|
100 |
Female |
18 Years and older (Adult, Senior) |
NCT03283384 |
BOOG-2017-01
2017-000676-29 |
NEOLBC |
February 2018 |
July 2020 |
February 2025 |
September 14, 2017 |
February 6, 2018 |
|
- Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands - Ziekenhuisgroep Twente (Twenteborg ZH Almelo)
Almelo, Netherlands - Ziekenhuis Amstelland
Amstelveen, Netherlands - (and 20 more...)
|
| 16 |
NCT03323346 |
Recruiting |
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer |
- Breast Neoplasm Female
- Metastatic Breast Cancer
|
|
Interventional |
Phase 2 |
- Marian Hajduch, M.D., Ph.D.
- University Hospital Olomouc
- The Institute of Molecular and Translational Medicine, Czech Republic
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical response rate (RR)
- Clinical benefit rate (CBR)
- Time to progression (TTP)
- (and 7 more...)
|
150 |
Female |
18 Years and older (Adult, Senior) |
NCT03323346 |
2016-1-DSF-MBC |
DISC |
September 29, 2017 |
December 31, 2019 |
September 30, 2020 |
October 27, 2017 |
October 27, 2017 |
|
- University Hospital Olomouc
Olomouc, Czechia
|
| 17 |
NCT03275727 |
Not yet recruiting |
A Guided Internet-delivered Individually-tailored ACT-influenced CBT Intervention to Improve Psychosocial Outcomes in Breast Cancer |
|
|
Interventional |
Phase 2
Phase 3 |
- Linkoeping University
- Escola Nacional de Saúde Pública - Universidade Nova de Lisboa
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Depression
- Anxiety
- Psychological flexibility
- (and 5 more...)
|
128 |
Female |
18 Years and older (Adult, Senior) |
NCT03275727 |
INNOVBC |
INNOVBC |
February 2018 |
December 2019 |
December 2019 |
September 8, 2017 |
September 8, 2017 |
|
|
| 18 |
NCT02480842 |
Recruiting |
Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction |
|
- Other: Alloplastic free ROM
- Other: Alloplastic limited ROM
- Other: Oncoplastic free ROM
- Other: Oncoplastic limited ROM
|
Interventional |
Not Applicable |
- Federal University of São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 07 days after surgery assessment
- Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 15 days after surgery assessment
- Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 30 days after surgery assessment
- (and 21 more...)
|
120 |
Female |
18 Years and older (Adult, Senior) |
NCT02480842 |
FUSaoPaulo PT 3 |
|
June 2015 |
June 2018 |
|
June 25, 2015 |
June 29, 2015 |
|
- Federal University of São Paulo
São Paulo, Brazil
|
| 19 |
NCT02744079 |
Not yet recruiting |
Comparison of Healthy Diets on Breast Cancer Markers |
|
- Behavioral: Low carbohydrate diet
- Behavioral: Low fat diet
|
Interventional |
Not Applicable |
- Albert Einstein College of Medicine, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- TUNEL comparison of each dietary intervention at surgical removal to measure change in apoptosis in tumor cells
- Ki-67 comparison of each dietary intervention at surgical removal to measure change in proliferation of tumor cells
|
65 |
Female |
21 Years and older (Adult, Senior) |
NCT02744079 |
2016-6346 |
KetoBreast |
February 20, 2018 |
September 2019 |
September 2020 |
April 20, 2016 |
January 11, 2018 |
|
- The Albert Einstein College of Medicine of Yeshiva University
Bronx, New York, United States
|
| 20 |
NCT03423199 |
Recruiting |
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY |
|
- Drug: Palbociclib
- Drug: Placebo
- Drug: Tamoxifen
- Drug: Goserelin
|
Interventional |
Phase 3 |
- National Cancer Center, Japan
- Pfizer
- Korean Cancer Study Group
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Overall Survival (OS)
- Survival Probabilities at 1 year, 2 year, and 3 year
- (and 8 more...)
|
180 |
Female |
18 Years and older (Adult, Senior) |
NCT03423199 |
NCCH1607
WI217662 |
PATHWAY |
February 9, 2018 |
February 2022 |
February 2022 |
February 6, 2018 |
April 3, 2018 |
|
- Aichi Cancer Center Hospital
Nagoya, Aichi, Japan - National Cancer Center Hospital East
Kashiwa, Chiba, Japan - National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan - (and 9 more...)
|
| 21 |
NCT03284567 |
Recruiting |
Football Fitness After Breast Cancer |
|
- Behavioral: Football fitness
|
Interventional |
Not Applicable |
- University of Copenhagen
- University of Southern Denmark
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Mean change in fitness level (maximal oxygen uptake) from baseline to month 6 and month 12.
- Mean change in whole-body fat mass from baseline to month 6 and month 12.
- Mean change in whole-body weight from baseline to month 6 and month 12.
- (and 13 more...)
|
90 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT03284567 |
FFABC |
FFABC |
March 20, 2017 |
April 30, 2019 |
April 30, 2019 |
September 15, 2017 |
September 15, 2017 |
|
- University Hospital of Copenhagen, Rigshospitalet
Copenhagen, Denmark
|
| 22 |
NCT03220178 |
Recruiting |
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy |
|
- Drug: Palbociclib
- Drug: Fulvestrant
- Drug: Anastrozole
- (and 2 more...)
|
Interventional |
Phase 4 |
- Palleos Healthcare GmbH
- WSG WOMEN´S HEALTHCARE STUDY GROUP
- CANKADO
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- DQoL
- Progression-free survival
- Overall survival
- (and 2 more...)
|
960 |
Female |
18 Years and older (Adult, Senior) |
NCT03220178 |
PH001-PreCycle |
PRECYCLE |
June 20, 2017 |
June 30, 2021 |
December 31, 2023 |
July 18, 2017 |
April 24, 2018 |
|
- University Hospital Mainz
Mainz, Germany
|
| 23 |
NCT02065960 |
Recruiting |
Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer |
|
- Radiation: Stereotactic body radiotherapy (SBRT)
|
Interventional |
Phase 1 |
- Juravinski Cancer Center
- Juravinski Cancer Centre Foundation
- Canadian Breast Cancer Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility
- Acute Radiation Toxicity
- Late Radiation Toxicity
- (and 3 more...)
|
32 |
Female |
70 Years and older (Senior) |
NCT02065960 |
13-699 |
ARTEMIS |
February 2014 |
June 2016 |
June 2020 |
February 19, 2014 |
March 31, 2015 |
|
- Juravinski Cancer Centre
Hamilton, Ontario, Canada
|
| 24 |
NCT03447132 |
Recruiting |
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant |
|
- Drug: Fulvestrant 500mg
- Drug: Palbociclib 125mg
- Drug: Goserelin 3.6 MG
- Drug: Placebos
|
Interventional |
Phase 3 |
- International Cancer Research Group, United Arab Emirates
- AstraZeneca
- Pfizer
- Genomic Health®, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- pCR according to Le Chevalier's classification
- pCR according to Sataloff's classification
- radiological response
- (and 3 more...)
|
400 |
Female |
18 Years and older (Adult, Senior) |
NCT03447132 |
ICRG1201 |
SAFIA |
January 1, 2018 |
September 1, 2023 |
September 1, 2023 |
February 27, 2018 |
February 27, 2018 |
|
- Cancer Center - Blida
Blida, Algeria - CHU - Oran
Oran, Algeria - King Hussein Cancer Center (KHCC) - Amman
Amán, Jordan - Oncology Center- King Saud University Medical City (KSUMC)
Riyadh, Saudi Arabia
|
| 25 |
NCT01176916 |
Recruiting |
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China |
|
- Drug: Aromasin (exemestane)
|
Interventional |
Phase 4 |
|
Industry |
- Masking: None (Open Label)
|
- Time-to-event, where event is defined as the earliest occurrence any of the following: Locoregional/distant recurrence of the primary breast cancer; Appearance of 2nd primary or contralateral breast cancer; Death
- The proportion of subjects experiencing the event
- The incidence rate (per annum) defined as a ratio of the number of events and the total exposure times (in years) to Aromasin® therapy
- (and 2 more...)
|
550 |
Female |
Child, Adult, Senior |
NCT01176916 |
A5991093
NRA5990043 |
|
February 9, 2011 |
December 1, 2018 |
December 1, 2018 |
August 6, 2010 |
April 18, 2018 |
|
- The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department
Bengbu, Anhui, China - The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China - The Second Hospital of Anhui Medical University
Hefei, Anhui, China - (and 50 more...)
|
| 26 |
NCT03242551 |
Recruiting |
Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer |
|
|
Interventional |
Phase 2 |
- Shenzhen People's Hospital
|
Other |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- pathological complete response (pCR)
- Response rate
- Disease free survival
- Overall survival
|
120 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT03242551 |
Shenzhen BC-001 |
BINC-B |
November 8, 2017 |
August 31, 2022 |
December 31, 2022 |
August 8, 2017 |
November 14, 2017 |
|
- Department of Oncology
Shenzhen, Guangdong, China - Shenzhen People Hospital
Shenzhen, Guangdong, China
|
| 27 |
NCT03039127 |
Recruiting |
Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer |
|
- Device: Immunostimulating Interstitial Laser Thermotherapy
|
Interventional |
Not Applicable |
- Clinical Laserthermia Systems AB
- Nottingham University Hospitals NHS Trust
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment effect by radiology
- Safety (adverse events)
- Usability (user evaluation of instrument)
|
5 |
All |
Child, Adult, Senior |
NCT03039127 |
CTP-2015-009 |
|
June 2016 |
February 2018 |
August 2018 |
February 1, 2017 |
February 2, 2017 |
|
- Nottingham Breast Cancer Institute
Nottingham, United Kingdom
|
| 28 |
NCT03269981 |
Recruiting |
Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer |
|
- Radiation: Whole breast irradiation
- Radiation: Whole breast and nodal irradiation
|
Interventional |
Not Applicable |
- Samsung Medical Center
- Korean Radiation Oncology Group
- Ministry of health & welfare, Republic of Korea
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival
- Disease-free survival according to molecular subtype
- Treatment-related toxicity
- Quality of life
|
1926 |
Female |
20 Years to 70 Years (Adult, Senior) |
NCT03269981 |
SMC 2017-01-085-001 |
|
April 1, 2017 |
March 30, 2021 |
March 30, 2023 |
September 1, 2017 |
September 1, 2017 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
| 29 |
NCT03242616 |
Recruiting |
PemVin vs Vin in Previously Treated Metastatic Breast Cancer |
|
- Drug: Pemetrexed + Vinorelbine
- Drug: Vinorelbine
|
Interventional |
Phase 2 |
- Seoul National University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression free survival
- response rate
- duration of response
- overall survival
|
125 |
All |
20 Years and older (Adult, Senior) |
NCT03242616 |
H1607-172-780 |
|
February 17, 2017 |
December 31, 2019 |
December 31, 2019 |
August 8, 2017 |
August 8, 2017 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
| 30 |
NCT03266562 |
Recruiting |
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography |
|
- Diagnostic Test: F-18 FES
- Diagnostic Test: F-18 FDG
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- correlation of FES and estrogen receptors
- correlation of FES and FDG in breast tumors
|
20 |
Female |
40 Years to 90 Years (Adult, Senior) |
NCT03266562 |
16-007764 |
PEM-FES |
April 1, 2018 |
April 2019 |
December 2019 |
August 30, 2017 |
March 21, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 31 |
NCT02781805 |
Recruiting |
Pilot Study of Bisphosphonates for Breast Cancer |
|
|
Interventional |
Phase 1 |
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
- Wisconsin Partnership Program
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Percentage change of γδ T cell in CNB
- Percentage change of mammary epithelial basal and luminal cells in the CNB samples after alendronate administration
|
20 |
Female |
18 Years and older (Adult, Senior) |
NCT02781805 |
UW13060
P30CA014520
2016-0322 |
|
August 2016 |
January 1, 2019 |
August 1, 2019 |
May 24, 2016 |
February 22, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 32 |
NCT02866994 |
Recruiting |
Project Connect Online: An Internet-based Intervention for Women With Breast Cancer |
|
- Behavioral: Project Connect Online
- Behavioral: PCO PLUS
|
Interventional |
Not Applicable |
- Jonsson Comprehensive Cancer Center
- Susan G. Komen Breast Cancer Foundation
- Breast Cancer Research Foundation
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change of general and cancer-related psychological status
- Change in overall physical health status
|
64 |
Female |
18 Years and older (Adult, Senior) |
NCT02866994 |
14-001744
20155036
SAC110009 |
PCO |
June 4, 2015 |
December 31, 2018 |
December 31, 2019 |
August 15, 2016 |
November 14, 2017 |
|
- University of California, Los Angeles
Los Angeles, California, United States
|
| 33 |
NCT03024580 |
Recruiting |
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer |
|
- Drug: Megestrol Acetate 160Mg Tablet
- Drug: Anastrozole 1Mg Tablet
- Drug: Letrozole 2.5Mg Tablet
- (and 3 more...)
|
Interventional |
Phase 2 |
- Instituto Nacional de Cancer, Brazil
- Cancer Research UK Cambridge Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Overall survival
- Clinical benefit
|
20 |
Female |
Child, Adult, Senior |
NCT03024580 |
64/16 |
MEGA |
March 6, 2017 |
March 2018 |
September 2018 |
January 19, 2017 |
December 6, 2017 |
|
- Hospital do Cancer III
Rio de Janeiro, Brazil
|
| 34 |
NCT02547545 |
Recruiting |
Breast Cancer Chemotherapy Risk Prediction Mathematical Model |
|
|
Observational |
|
- First Affiliated Hospital Xi'an Jiaotong University
- Shaanxi Hospital of Traditional Chinese Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Myelosuppression of chemotherapy
- Chemotherapy related vomit (side effects of chemotherapy)
|
795 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT02547545 |
XJTU1AF2012LSK-021 |
BCCRPMM |
September 2015 |
March 2017 |
May 2017 |
September 11, 2015 |
August 10, 2016 |
|
- First Affiliated Hospital of Xian Jiaotong University
Xi'an, China
|
| 35 |
NCT03273426 |
Recruiting |
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy. |
|
- Device: core needle biopsy
- Device: vacuum-assisted biopsy
|
Interventional |
Not Applicable |
- Seoul National University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Negative predictive value
- false negative rate
|
40 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT03273426 |
SNUHBCC002 |
|
September 8, 2016 |
October 2017 |
December 2017 |
September 6, 2017 |
September 6, 2017 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
| 36 |
NCT02491957 |
Recruiting |
Impact of LOFT Therapy™ on Breast Cancer Survivors |
|
|
Interventional |
Not Applicable |
- Kathy Miller
- Indiana University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Feasibility of LOFT therapy in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy
- Safety of LOFT intervention in this population patient reported adverse events
- Heart rate
- (and 9 more...)
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02491957 |
IUSCC-0539 |
|
July 28, 2015 |
March 29, 2018 |
March 29, 2019 |
July 8, 2015 |
June 2, 2017 |
|
- Indiana University Health Hospital
Indianapolis, Indiana, United States - Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
|
| 37 |
NCT03124095 |
Recruiting |
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer |
|
- Behavioral: Combined exercise Group
|
Interventional |
Not Applicable |
- Federal University of Pelotas
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Cardiorespiratory Fitness evaluation change after 8 weeks
- Quality of Life change after 8 weeks (Score)
- Maximal dynamic strength change after 8 weeks (kg)
- (and 4 more...)
|
42 |
Female |
18 Years and older (Adult, Senior) |
NCT03124095 |
+Vida-Breast cancer |
+Vida |
September 2016 |
July 2017 |
December 2017 |
April 21, 2017 |
April 21, 2017 |
|
- Physical Education School
Pelotas, RS, Brazil
|
| 38 |
NCT02938442 |
Not yet recruiting |
Vaccination of Triple Negative Breast Cancer Patients |
|
- Biological: P10s-PADRE with MONTANIDE™ ISA 51 VG
- Drug: Standard Chemotherapy
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- rate of pCR in breast and axillary lymph nodes
|
102 |
Female |
18 Years and older (Adult, Senior) |
NCT02938442 |
206010 |
|
October 2018 |
November 2020 |
November 2020 |
October 19, 2016 |
November 9, 2017 |
|
- Highlands Oncology Group
Fayetteville, Arkansas, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
|
| 39 |
NCT03202862 |
Not yet recruiting |
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer |
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
50 |
Female |
Child, Adult, Senior |
NCT03202862 |
Fulvestrant in ESR1 Mutated BC |
|
July 1, 2017 |
June 1, 2019 |
August 1, 2019 |
June 29, 2017 |
June 29, 2017 |
|
|
| 40 |
NCT02982564 |
Recruiting |
Effect of Low vs Moderate-intensity Endurance Exercise on Physical Functioning Among Breast Cancer Survivors |
|
- Behavioral: Exercise Program Low Intensity
- Behavioral: Exercise Program Moderate Intensity
|
Interventional |
Not Applicable |
- University of Puerto Rico
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change in Cardiovascular fitness: Six-minute walk test
- Change in Quality of Life
- Change in Functioning
- (and 5 more...)
|
142 |
Female |
50 Years and older (Adult, Senior) |
NCT02982564 |
1SC3GM116684-01 |
|
March 2016 |
February 2020 |
February 2020 |
December 5, 2016 |
June 7, 2017 |
|
- Puerto Rico Clinical and Translational Research Consortium
San Juan, Puerto Rico
|
| 41 |
NCT02819882 |
Recruiting |
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) |
|
|
Observational |
|
- Spanish Breast Cancer Research Group
- Hoffmann-La Roche
- Novartis
- (and 3 more...)
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients with the different breast cancer subtypes and real distribution of them.
- Breast cancer and heredofamiliar risk according with the patient and tumor characteristics.
- Differences in the development disease in the group of male vs female patients.
- (and 7 more...)
|
1400 |
All |
18 Years and older (Adult, Senior) |
NCT02819882 |
GEICAM 2014-03 |
REGISTEM |
June 2016 |
June 2024 |
June 2024 |
June 30, 2016 |
January 11, 2018 |
|
- Hospital General de Elche
Elche, Alicante, Spain - Althaia-Xarxa Assistencial de Manresa
Manresa, Barcelona, Spain - Consorci Sanitari de Terrassa
Terrassa, Barcelona, Spain - (and 38 more...)
|
| 42 |
NCT02898727 |
Recruiting |
A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer |
|
|
Interventional |
Phase 2 |
- Trans-Tasman Radiation Oncology Group (TROG)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- to assess the percentage of patients treated with whole brain radiotherapy within 12 months after completion of local therapy
- To describe distant brain failure incidence (overall and by number of treated metastases)
- To describe local brain failure incidence, at any site of SRS or surgery
- (and 5 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02898727 |
TROG 16.02 |
Local HER-O |
November 20, 2017 |
May 2020 |
May 2020 |
September 13, 2016 |
February 28, 2018 |
|
- Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
|
| 43 |
NCT02740491 |
Recruiting |
Implementation of a "Remission" Consultation in the Management of Patients Treated for Localized Breast Cancer |
|
- Other: Remission Consultation
|
Observational |
|
- Centre Hospitalier Universitaire de Nīmes
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- The EORTC QLQ-C30 questionnaire
- Body Image Scale
- Psychological distress (visual analog scale)
- (and 2 more...)
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT02740491 |
LOCAL/2016/LD-01 |
REVIS |
September 2016 |
September 2018 |
September 2018 |
April 15, 2016 |
November 1, 2017 |
|
- CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes Cedex 09, France
|
| 44 |
NCT03280563 |
Recruiting |
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer |
|
- Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
- Drug: Bevacizumab
- Drug: Cobimetinib
- (and 4 more...)
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Objective Response during Stage 1 According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
- Progression-Free Survival during Stage 1 According to RECIST v1.1
- Percentage of Participants with Clinical Benefit during Stage 1 According to RECIST v1.1
- (and 17 more...)
|
111 |
Female |
18 Years and older (Adult, Senior) |
NCT03280563 |
CO39611
2017-000335-14 |
MORPHEUS |
September 30, 2017 |
April 30, 2021 |
October 7, 2022 |
September 12, 2017 |
April 13, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Cedars-Sinai Medical Center
Los Angeles, California, United States - UCSF Helen Diller Family CCC
San Francisco, California, United States - (and 14 more...)
|
| 45 |
NCT02316561 |
Recruiting |
Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer |
|
- Radiation: Single dose ablative radiotherapy
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathological complete response
- Radiological tumor response on MRI according to the RECIST criteria
- Radiological tumor response on FDG-PET-CT according to the PERCIST criteria
- (and 9 more...)
|
25 |
Female |
50 Years and older (Adult, Senior) |
NCT02316561 |
NL46017.041.13 |
ABLATIVE |
October 2014 |
May 2018 |
May 2028 |
December 15, 2014 |
January 20, 2017 |
|
- University Medical Center Utrecht
Utrecht, Netherlands
|
| 46 |
NCT02718144 |
Recruiting |
Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer |
|
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The number of patients with a dose limiting toxicity (DLT)
- Questionnaire on estrogen deficiency symptoms
- Pharmacokinetics: estetrol trough levels
- Preliminary anti-tumour response according to RECIST 1.1
|
18 |
Female |
Child, Adult, Senior |
NCT02718144 |
PR3106 |
|
June 1, 2017 |
October 2018 |
October 2018 |
March 24, 2016 |
March 30, 2018 |
|
- Katholisches Klinikum Koblenz Montabaur
Koblenz, Germany - Katholisches Klinikum Mainz
Mainz, Germany - Universitatsmedizin Mainz
Mainz, Germany
|
| 47 |
NCT02934815 |
Recruiting |
Relational and Emotional Mechanisms of a Supportive-expressive Group Intervention in Breast Cancer |
- Breast Neoplasms
- Breast Cancer
|
- Other: Supportive-expressive group therapy
|
Interventional |
Not Applicable |
- Universidade do Porto
- Fundação para a Ciência e a Tecnologia
- Centro Hospitalar de Vila Nova de Gaia/Espinho
- (and 2 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in quality of life across time
- Change in emotion suppression across time
- Change in emotional self-efficacy across time
- (and 4 more...)
|
50 |
Female |
30 Years to 65 Years (Adult) |
NCT02934815 |
FPCEUP/BreastCancerCare |
BC-SEGT |
January 2015 |
January 2017 |
January 2017 |
October 17, 2016 |
October 17, 2016 |
|
- Tânia Brandão
Porto, Portugal
|
| 48 |
NCT02756364 |
Recruiting |
MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy |
|
- Drug: Fulvestrant
- Drug: MLN0128
|
Interventional |
Phase 2 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Overall Survival (OS)
- Time to Progression (TTP)
- (and 3 more...)
|
153 |
Female |
18 Years and older (Adult, Senior) |
NCT02756364 |
C31006
2015-003612-20
U1111-1174-2165 |
|
June 1, 2016 |
May 1, 2018 |
May 1, 2018 |
April 29, 2016 |
March 26, 2018 |
|
- Southern Cancer Center, PC
Mobile, Alabama, United States - Arizona Oncology Associates, PC, NAHOA
Sedona, Arizona, United States - Arizona Oncology Associates, PC- HOPE
Tucson, Arizona, United States - (and 62 more...)
|
| 49 |
NCT02271828 |
Recruiting |
Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy |
|
- Procedure: Sentinel lymph node procedure
|
Interventional |
Not Applicable |
- Maastricht University Medical Center
- Borstkanker Onderzoek Groep
- Dutch Cancer Society
- Maastricht University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
1644 |
Female |
18 Years and older (Adult, Senior) |
NCT02271828 |
BOOG 2013-08
KWF UM 2014-6679 |
|
April 2015 |
April 2027 |
April 2027 |
October 22, 2014 |
April 21, 2017 |
|
- Maastricht University Medical Centre+
Maastricht, Limburg, Netherlands - Flevoziekenhuis
Almere, Netherlands - Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands - (and 19 more...)
|
| 50 |
NCT02620735 |
Recruiting |
Smart-phone Health Coaching Intervention to Promote Maintenance of Exercise in Breast Cancer Survivors:Protocol |
|
- Device: Fit bit Device
- Behavioral: Exercise Only
- Behavioral: Connected Wellness HealthCoach Software
- Behavioral: Health Coaching
|
Interventional |
Not Applicable |
- University Health Network, Toronto
- Canadian Breast Cancer Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Recruitment Rate
- Retention Rate
- Capture of Outcomes - proportion of participants from whom complete information is derived on clinical outcomes.
- (and 15 more...)
|
107 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT02620735 |
13-6157-DE |
iMOVE |
December 2014 |
December 2016 |
July 2017 |
December 3, 2015 |
August 9, 2016 |
|
- ELLICSR, Toronto General Hospital 200 Elizabeth St.
Toronto, Ontario, Canada
|
Create an RSS feed from your search for:
Download the search results for: